Pediatric GHD: Working Together to Ensure Success

Offered in conjunction with The France Foundation, this program will cover many of the common difficulties and recommended approaches for dealing with pediatric GHD as offered by our expert panel.

Through this program, you will learn:

  1. How to review the safety and efficacy data of the rhGH therapies available for the management of GHD in pediatric patients;
  2. Proper assessment of novel and emerging rhGH agents and clinical implications for management of GHD in pediatric patients; and
  3. The importance and clinical implications of adherence to rhGH therapy in GHD in pediatric patients.

This course includes the recording of a recent webinar held on May 26 and an interactive online module, which will be available on June 4. Each activity is available for credit following completion of an evaluation. 

Target Audience

This educational initiative is intended for pediatric and general endocrinologists, family physicians, pediatricians, nurse practitioners, and physician assistants who are managing pediatric patients with GHD. 

Learning Objectives

  1. How to review the safety and efficacy data of the rhGH therapies available for the management of GHD in pediatric patients;
  2. Proper assessment of novel and emerging rhGH agents and clinical implications for management of GHD in pediatric patients; and
  3. The importance and clinical implications of adherence to rhGH therapy in GHD in pediatric patients.

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Growth Disorders
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Course opens: 
Course expires: 

Craig A. Alter, MD – Program Chair
Children's Hospital of Philadelphia
Philadelphia, PA

Adda Grimberg, MD
Perelman School of Medicine, University of Pennsylvania
Philadelphia, PA

Bradley S. Miller, MD, PhD
University of Minnesota Masonic Children's Hospital
Minneapolis, MN


As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

  • Craig A. Alter, MD: Advisory Board Member: Novo Nordisk; Consultant: OPKO Health
  • Adda Grimberg, MD: Grant Recipient: Pfizer Inc.
  • Bradley S. Miller, MD, PhD: Consultant: Ascendis Pharma, Abbvie, Biomarin, Orchard, Pfizer Inc., Novo Nordisk, Sandoz Inc., Sanofi Genzyme, Tolmar, and Vertice. Research Investigator: Alexion, Abbvie, Amgen, Ascendis, Lumos Pharma, Novo Nordisk, OPKO Health, Pfizer Inc., Sandoz, and Tolmar. He will discuss off-label use of medications since these medications are being developed.

The following SPC member who planned and reviewed content for this activity reported relevant financial relationships:

  • Andjela T. Drincic, MD: Advisory Board Member: Corcept Therapeutics

The following member who reviewed content for this activity reported relevant financial relationships:

  • Selma F. Witchel, MD

The following SPC members reported no relevant financial relationships: Howard S. Blank, MD; Beret Ann Casey, MD; Lediya Cheru, MD; Marcelo Correia, MD, PhD; Angela M. Leung, MD; Kelly Lauter Roszko, MD, PhD; Virginia D. Sarapura, MD; Soleymani Taraneh, MD; Savitha Subramanian, MD

The ES and TFF staff involved in the development of this CME activity reported no relevant financial relationships.

DISCLAIMERS USE OF PROFESSIONAL JUDGMENT: The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES: When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE: The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


This educational activity is supported by educational grants from Pfizer Inc and Sandoz Inc.

Continuing Medical Education (ACCME) through the joint providership of Endocrine Society and The France Foundation. The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credit

The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)

Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Pediatrics (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at

Review your ABP Diplomate ID Number(s)

In order to earn and report MOC points to the American Board of Pediatrics (ABP), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers (must be logged in to view):

    Your ABP Number: [current-user:profile-profile:field-number-abp]*

    *If your ABP number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.

  2. Update Profile